Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/24636Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Elisaf, M. S. | en |
| dc.contributor.author | Bairaktari, E. | en |
| dc.contributor.author | Nicolaides, C. | en |
| dc.contributor.author | Fountzilas, G. | en |
| dc.contributor.author | Tzallas, C. | en |
| dc.contributor.author | Siamopoulos, K. | en |
| dc.contributor.author | Tsolas, O. | en |
| dc.contributor.author | Pavlidis, N. | en |
| dc.date.accessioned | 2015-11-24T19:42:24Z | - |
| dc.date.available | 2015-11-24T19:42:24Z | - |
| dc.identifier.issn | 0250-7005 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/24636 | - |
| dc.rights | Default Licence | - |
| dc.subject | Aged | en |
| dc.subject | Cholesterol, HDL/blood/drug effects | en |
| dc.subject | Cholesterol, LDL/blood/drug effects | en |
| dc.subject | Female | en |
| dc.subject | Humans | en |
| dc.subject | Hypolipidemic Agents/*pharmacology | en |
| dc.subject | Lipoprotein(a)/blood/*drug effects | en |
| dc.subject | Middle Aged | en |
| dc.subject | Prospective Studies | en |
| dc.subject | Tamoxifen/*pharmacology | en |
| dc.title | The beneficial effect of tamoxifen on serum lipoprotein-A levels: an additional anti-atherogenic property | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/8917378 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 1996 | - |
| heal.abstract | It has recently been suggested that increased lipoprotein (a) levels are an independent risk factor for coronary heart disease. It has also been reported that tamoxifen can induce changes in blood lipid values. In this prospective study we investigated the long term effects tamoxifen on the lipid profile, focusing on lipoprotein (a) levels. Thirty-eight postmenopausal women with breast cancer treated with tamoxifen at a dose of 20 mg daily were studied. The mean age was 61 years. Serum lipoprotein (a) levels and lipid parameters (total cholesterol, high and low density lipoprotein cholesterol, triglycerides, apolipoprotein A-I and B) were measured after an overnight fast on the 1, 3, 6 and 9 month of tamoxifen treatment. A progressive fall in median lipoprotein(a) levels from 8 mg/dl to 3 mg/dl (p < 0.001) was observed. In addition, a significant decrease in the total and low density lipoprotein cholesterol and in apolipoprotein B, as well as an increase in apolipoprotein A-l were also noticed. It is concluded that our data on serum lipoprotein(a) levels agree with the beneficial anti-atherogenic effects of tamoxifen administration on lipoproteins. | en |
| heal.journalName | Anticancer Res | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
